NTRK gene fusions are detected in both secretory and non‐secretory breast cancers
- 31 January 2022
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 72 (3) , 187-192
Abstract
NTRK fusions represent a new biomarker‐defined population that can be treated with TRK inhibitors. Although rare, NTRK fusions are detected across a wide range of solid tumors. Previous reports suggest that NTRK fusions are limited to the secretory subtype of breast cancer. Here we examined NTRK fusions in a large real world next‐generation sequencing (NGS) dataset and confirmed secretory versus non‐secretory status using H&E images. Of 23 NTRK fusion‐positive cases, 11 were classified as secretory, 11 as non‐secretory, and one as mixed status. The secretory subtype trended younger, was predominantly estrogen receptor (ER)–, had lower tumor mutational burden, and exhibited lower levels of genomic loss of heterozygosity. The non‐secretory subtype was enriched for TP53 mutations. The secretory subtype was enriched for ETV6‐NTRK3 fusions in 7 of 11 cases, and the non‐secretory subtype had NTRK1 fusions in 7 of 11 cases, each with a different fusion partner. Our data suggests NTRK fusions are present in both secretory and non‐secretory subtypes, and that comprehensive genomic profiling should be considered across all clinically advanced breast cancers to identify patients that could receive benefit from TRK inhibitors.Keywords
Funding Information
- Roche
This publication has 20 references indexed in Scilit:
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2017
- Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data BaseJournal of Surgical Oncology, 2016
- TRKing Down an Old Oncogene in a New Era of Targeted TherapyCancer Discovery, 2015
- Mammary Analogue Secretory Carcinoma of Salivary Glands With High-grade TransformationAmerican Journal of Surgical Pathology, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomesNucleic Acids Research, 2013
- A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinomaGenes, Chromosomes and Cancer, 2004
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinomaCancer Cell, 2002